Syndax Pharmaceuticals, Inc. ($SNDX)
Filing Information
| Accession Number | 0001193125-26-041497 |
|---|---|
| Form Type | 4 |
| Filing Date | Feb 6, 2026 |
| Document Date | Feb 4, 2026 |
| Document | View SEC Filing |
Transactions
5
Total Shares
173,551
Total Value
$2,464,007.96
P&L
+73.4% (+$1,768,914.53)
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | Common Stock | โ | Jan 30, 2026 | Other Acquisition or Disposition | 1,219 | $8.48 | $10,337.12 | 93,671 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Feb 4, 2026 | Grant/Award | 21,500 | $0.00 | $0.00 | 115,171 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Feb 4, 2026 | Grant/Award | 30,750 | $0.00 | $0.00 | 145,921 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Feb 6, 2026 | Sale | 2,082 | $20.62 | $42,930.84 | 143,839 | Direct | โ | View Details | |
Chief Financial Officer | Stock Options (Right to buy) | Derivative | Feb 4, 2026 | Grant/Award | 118,000 | $20.43 | $2,410,740.00 | 118,000 | Direct | โ | View Details |